Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1001/jamanetworkopen.2022.2973 http://scihub22266oqcxt.onion/10.1001/jamanetworkopen.2022.2973 35302631!8933746!35302631     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       JAMA+Netw+Open 2022 ; 5 (3): e222973 Nephropedia Template TP {{tp|p=35302631|t=2022. The Fragility of Statistically Significant Results in Randomized Clinical Trials for COVID-19 |pdf=|usr=}}{{35302631}} gab.com Text The Fragility of Statistically Significant Results in Randomized Clinical Trials for COVID-19 JO: JAMA Netw Open http://www.kidney.de/pget.php?&tw=1&pmid=35302631 #FOAvip IMPORTANCE: Interpreting results from randomized clinical trials (RCTs) for COVID-19, which have been published rapidly and in vast numbers, is challenging during a pandemic. OBJECTIVE: To evaluate the robustness of statistically significant findings from RCTs for COVID-19 using the fragility index. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study included COVID-19 trial articles that randomly assigned patients 1:1 into 2 parallel groups and reported at least 1 binary outcome as significant in the abstract. A systematic search was conducted using PubMed to identify RCTs on COVID-19 published until August 7, 2021. EXPOSURES: Trial characteristics, such as type of intervention (treatment drug, vaccine, or others), number of outcome events, and sample size. MAIN OUTCOMES AND MEASURES: Fragility index. RESULTS: Of the 47 RCTs for COVID-19 included, 36 (77%) were studies of the effects of treatment drugs, 5 (11%) were studies of vaccines, and 6 (13%) were of other interventions. A total of 138?235 participants were included in these trials. The median (IQR) fragility index of the included trials was 4 (1-11). The medians (IQRs) of the fragility indexes of RCTs of treatment drugs, vaccines, and other interventions were 2.5 (1-6), 119 (61-139), and 4.5 (1-18), respectively. The fragility index among more than half of the studies was less than 1% of each sample size, although the fragility index as a proportion of events needing to change would be much higher. CONCLUSIONS AND RELEVANCE: This cross-sectional study found a relatively small number of events (a median of 4) would be required to change the results of COVID-19 RCTs from statistically significant to not significant. These findings suggest that health care professionals and policy makers should not rely heavily on individual results of RCTs for COVID-19. Twit Text FOAVip The Fragility of Statistically Significant Results in Randomized Clinical Trials for COVID-19 ????JAMA Netw Open http://www.kidney.de/pget.php?&tw=1&pmid=35302631 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35302631 #FOAvip English Wikipedia <ref>{{Cite pmid|35302631}}</ref> The Fragility of Statistically Significant Results in Randomized Clinical Trials for COVID-19 #MMPMID35302631 Itaya T; Isobe Y; Suzuki S; Koike K; Nishigaki M; Yamamoto Y JAMA Netw Open 2022[Mar]; 5 (3): e222973 PMID35302631show ga IMPORTANCE: Interpreting results from randomized clinical trials (RCTs) for COVID-19, which have been published rapidly and in vast numbers, is challenging during a pandemic. OBJECTIVE: To evaluate the robustness of statistically significant findings from RCTs for COVID-19 using the fragility index. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study included COVID-19 trial articles that randomly assigned patients 1:1 into 2 parallel groups and reported at least 1 binary outcome as significant in the abstract. A systematic search was conducted using PubMed to identify RCTs on COVID-19 published until August 7, 2021. EXPOSURES: Trial characteristics, such as type of intervention (treatment drug, vaccine, or others), number of outcome events, and sample size. MAIN OUTCOMES AND MEASURES: Fragility index. RESULTS: Of the 47 RCTs for COVID-19 included, 36 (77%) were studies of the effects of treatment drugs, 5 (11%) were studies of vaccines, and 6 (13%) were of other interventions. A total of 138?235 participants were included in these trials. The median (IQR) fragility index of the included trials was 4 (1-11). The medians (IQRs) of the fragility indexes of RCTs of treatment drugs, vaccines, and other interventions were 2.5 (1-6), 119 (61-139), and 4.5 (1-18), respectively. The fragility index among more than half of the studies was less than 1% of each sample size, although the fragility index as a proportion of events needing to change would be much higher. CONCLUSIONS AND RELEVANCE: This cross-sectional study found a relatively small number of events (a median of 4) would be required to change the results of COVID-19 RCTs from statistically significant to not significant. These findings suggest that health care professionals and policy makers should not rely heavily on individual results of RCTs for COVID-19. |COVID-19/*therapy[MESH] |Cross-Sectional Studies[MESH] |Humans[MESH] |Outcome Assessment, Health Care[MESH] |Randomized Controlled Trials as Topic[MESH] |Reproducibility of Results[MESH]The Fragility of Statistically Significant Results in Randomized Clini(epmc).pdf DeepDyve Pubget Overpricing